You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
A&I Pharmaceuticals reported third-quarter revenue of $290.8 million and adjusted EBITDA of $83.3 million, cut 2026 gel revenue guidance to $480 million to $500 million, and offered $560 million for Aegida Therapeutics.
ANI Pharmaceuticals launched a recommended public cash offer for Egetis Therapeutics worth approximately SEK 5.6 billion, supported by a $676 million senior bridge facility with JPMorgan Chase Bank, N.A.; shareholders representing 42.2% committed to accept.
Ani Pharmaceuticals reported nine-month 2026 net revenues of $794.3 million, up 24.8%, and net income of $89,352 thousand, versus $636.3 million and $50,847 thousand a year earlier. Cortrophin Gel sales rose 40.0%, while Rare Disease and Brands revenue increased 39.8%.
ANI Pharmaceuticals reported third-quarter net revenues of $290.8 million, up 27.6%, and adjusted non-GAAP EBITDA of $83.3 million, up 39.8%. It proposed acquiring Egetis Therapeutics for SEK 11.25 per share, valuing the offer at approximately SEK 5.6 billion.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Q3 revenue, Rare Disease revenue, EBITDA, gross margin and Generics revenue grew strongly, while ANI raised EBITDA, EPS and ILUVIEN guidance and Cortrophin demand remained strong. Risks included slower Cortrophin revenue conversion and lower guidance, declining Brands revenue, higher operating expenses, and year-one EPS dilution from the proposed Egetis acquisition.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP Adjusted Diluted Weighted-Average Shares Outstanding (excluded shares) non-GAAP | 345,000 | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANIP
this stock
Ani Pharmaceuticals Inc
|
$1.62B | -9.5% | +2.5% | 14.0 | 15.8% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
ANI Pharmaceuticals reported third-quarter net revenues of $290.8 million, up 27.6%, and adjusted non-GAAP EBITDA of $83.3 million, up 39.8%. It proposed acquiring Egetis Therapeutics for SEK 11.25 per share, valuing the offer at approximately SEK 5.6 billion.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANIP | +6.0% | -1.2% | -12.3% | -0.8% | -9.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +3.4% | 0.0% | -12.8% | -0.6% | -20.1% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
